Maxim Maxamine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Oncologic Drugs Advisory Committee will consider histamine dihydrochloride at its Dec. 13-14 meeting as an adjuvant to interleukin-2 for the treatment of advanced metastatic melanoma. The NDA, submitted July 19, is under priority revie
|
FDA's Oncologic Drugs Advisory Committee will consider histamine dihydrochloride at its Dec. 13-14 meeting as an adjuvant to interleukin-2 for the treatment of advanced metastatic melanoma. The NDA, submitted July 19, is under priority review |